Abstract 9793: Temporal Trends in Utilization of Cardiovascular-Kidney-Metabolic Syndrome Directed Therapies Among Patients with HFpEF: A Contemporary Real-World Analysis of Over 1.2 Million Patients
Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) represents a central manifestation of cardiovascular-kidney-metabolic (CKM) syndrome and is associated with substantial cardiovascular and renal morbidity. Contemporary guidelines increasingly recommend CKM-directed therapies, including sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), mineralocorticoid receptor antagonists (MRA), and statins. However, real-world adoption of these therapies among patients with HFpEF remains poorly characterized. We evaluated temporal trends in CKM-directed pharmacotherapy utilization in a large contemporary HFpEF population. Methods: Using the TriNetX Research Network, we identified adults with HFpEF and concomitant CKM syndrome between 2019 and 2025. CKM syndrome was defined by the presence of obesity, diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease, or other cardiovascular disease. Utilization of guideline-supported CKM-directed therapies was assessed annually, including SGLT2 inhibitors, GLP-1 receptor agonists, mineralocorticoid receptor antagonists, and statins. Long-term cardiovascular and renal outcomes were evaluated descriptively. Results: A total of 1,264,674 patients with HFpEF and CKM syndrome were identified. Uptake of disease-modifying CKM therapies increased over time but remained low overall. SGLT2 inhibitor utilization increased from 1.8% in 2019 to 6.8% in 2025, while GLP-1 receptor agonist utilization increased from 1.2% to 4.6% during the same period. Despite growing evidence supporting these therapies, use remained limited, with only 85,383 patients (6.8%) receiving SGLT2 inhibitors and 57,702 patients (4.6%) receiving GLP-1 receptor agonists by study end. Mineralocorticoid receptor antagonist use remained modest, with spironolactone prescribed in 140,118 patients (11.1%) and finerenone in only 883 patients (0.1%). Statins were more frequently utilized, although substantial treatment gaps persisted. Over 5 years of follow-up, 783,364 patients (62.2%) experienced heart failure hospitalization, reflecting the substantial residual disease burden in this population. Conclusions: Among more than 1.2 million patients with HFpEF and CKM syndrome, utilization of evidence-based CKM-directed therapies increased between 2019 and 2025 but remained strikingly low despite a substantial burden of adverse clinical outcomes. These findings highlight persistent therapeutic inertia in the management of CKM syndrome and underscore the need for implementation strategies to accelerate adoption of disease-modifying therapies in patients with HFpEF.